These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 18711176)

  • 21. Provocative optimism in the treatment of early stage disease.
    Wolmark N
    Oncologist; 2005 Oct; 10 Suppl 2():1-3. PubMed ID: 16272452
    [No Abstract]   [Full Text] [Related]  

  • 22. Obesity and cancer treatment: weighing the evidence.
    Griggs JJ; Sabel MS
    J Clin Oncol; 2008 Sep; 26(25):4060-2. PubMed ID: 18757320
    [No Abstract]   [Full Text] [Related]  

  • 23. Does the decision in a validation process of a surrogate endpoint change with level of significance of treatment effect? A proposal on validation of surrogate endpoints.
    Sertdemir Y; Burgut R
    Contemp Clin Trials; 2009 Jan; 30(1):8-12. PubMed ID: 18809512
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase 0 clinical studies in oncology.
    Collins JM
    Clin Pharmacol Ther; 2009 Feb; 85(2):204-7. PubMed ID: 19109589
    [No Abstract]   [Full Text] [Related]  

  • 25. Effectiveness of treatments for metastatic uveal melanoma.
    Augsburger JJ; Corrêa ZM; Shaikh AH
    Am J Ophthalmol; 2009 Jul; 148(1):119-27. PubMed ID: 19375060
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor progression associated with erythropoiesis-stimulating agents.
    Newland AM; Black CD
    Ann Pharmacother; 2008 Dec; 42(12):1865-70. PubMed ID: 19017828
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Arrhenius relationships from the molecule and cell to the clinic.
    Dewey WC
    Int J Hyperthermia; 2009 Feb; 25(1):3-20. PubMed ID: 19219695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence-based study design in ocular allergy trials.
    Katelaris CH; Bielory L
    Curr Opin Allergy Clin Immunol; 2008 Oct; 8(5):484-8. PubMed ID: 18769206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive factors of outcome and tumor response to systemic chemotherapy in patients with metastatic hepatocellular carcinoma.
    Ikeda M; Okusaka T; Ueno H; Morizane C; Kojima Y; Iwasa S; Hagihara A
    Jpn J Clin Oncol; 2008 Oct; 38(10):675-82. PubMed ID: 18716041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Limitations of "pragmatic" trials.
    Ernst E; Canter PH
    Postgrad Med J; 2005 Apr; 81(954):203. PubMed ID: 15811880
    [No Abstract]   [Full Text] [Related]  

  • 31. Are onsite image evaluations the solution or are we trading one problem for another?
    Raunig DL
    J Clin Oncol; 2009 Dec; 27(35):e263-4; author reply e265. PubMed ID: 19901131
    [No Abstract]   [Full Text] [Related]  

  • 32. The prognostic value of tumor markers in newly diagnosed patients with primary central nervous system germ cell tumors.
    Kim A; Ji L; Balmaceda C; Diez B; Kellie SJ; Dunkel IJ; Gardner SL; Sposto R; Finlay JL
    Pediatr Blood Cancer; 2008 Dec; 51(6):768-73. PubMed ID: 18802946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progress in the curative treatment of childhood hematologic malignancies.
    Wayne AS; Reaman GH; Helman LJ
    J Natl Cancer Inst; 2008 Sep; 100(18):1271-3. PubMed ID: 18780861
    [No Abstract]   [Full Text] [Related]  

  • 34. Surrogate measures of outcome in clinical trials: clues worth examining?
    Carter BS; Awad IA
    Neurosurgery; 2008 Aug; 63(2):N5. PubMed ID: 18797341
    [No Abstract]   [Full Text] [Related]  

  • 35. Cancer clinical trial outcomes: any progress in tumour-size assessment?
    Verweij J; Therasse P; Eisenhauer E;
    Eur J Cancer; 2009 Jan; 45(2):225-7. PubMed ID: 19068275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer.
    Biankin AV; Kench JG; Colvin EK; Segara D; Scarlett CJ; Nguyen NQ; Chang DK; Morey AL; Lee CS; Pinese M; Kuo SC; Susanto JM; Cosman PH; Lindeman GJ; Visvader JE; Nguyen TV; Merrett ND; Warusavitarne J; Musgrove EA; Henshall SM; Sutherland RL;
    Gastroenterology; 2009 Aug; 137(2):558-68, 568.e1-11. PubMed ID: 19376121
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preferred designs, outcomes, and analysis strategies for treatment trials in idiopathic recurrent acute pancreatitis.
    Romagnuolo J; Guda N; Freeman M; Durkalski V
    Gastrointest Endosc; 2008 Nov; 68(5):966-74. PubMed ID: 18725158
    [No Abstract]   [Full Text] [Related]  

  • 38. Central pathology review in multicenter trials and studies: lessons from the nephroblastoma trials.
    Vujanić GM; Sandstedt B; Kelsey A; Sebire NJ
    Cancer; 2009 May; 115(9):1977-83. PubMed ID: 19241454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive factors for response and prognostic factors for long-term survival in consecutive, single institution patients with locally advanced and/or metastatic transitional cell carcinoma following cisplatin-based chemotherapy.
    Jessen C; Agerbaek M; Von Der Maase H
    Acta Oncol; 2009; 48(3):411-7. PubMed ID: 18798018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The type I error and power of non-parametric logrank and Wilcoxon tests with adjustment for covariates--a simulation study.
    Jiang H; Symanowski J; Paul S; Qu Y; Zagar A; Hong S
    Stat Med; 2008 Dec; 27(28):5850-60. PubMed ID: 18759373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.